Literature DB >> 10928134

Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.

A Gadducci1, P Iacconi, A Fanucchi, S Cosio, G Teti, A R Genazzani.   

Abstract

BACKGROUND: The impact of surgical cytoreduction performed during second-look on the survival of patients with advanced ovarian cancer is still under debate.
MATERIALS AND METHODS: The present retrospective investigation assessed 81 patients with advanced ovarian cancer who underwent second-look laparotomy after initial cytoreductive surgery and six cycles of platinum-based chemotherapy.
RESULTS: At the beginning of the second-look, 31 patients were in pathological complete response, 7 had microscopic residual disease, 22 had macroscopic residual disease < 2 cm and 21 had a larger residuum. Twenty-two (51.2%) of the 43 patients with macroscopic disease underwent surgical cytoreduction during the second-look: 11 patients were completely cytoreduced, whereas 11 were debulked from residuum > 2 cm to macroscopic residuum < 2 cm. Patients with microscopic residual disease after the second-look had improved survival when compared to those with macroscopic residuum after re-exploration (median survival, 43 months versus 19.5 months, p = 0.002). Among the former, no difference in survival was detected between the patients who had microscopic disease at the beginning of the second-look and those who were surgically cytoreduced to microscopic disease. Moreover, the patients with macroscopic residuum < 2 cm after the second-look had a better survival than those with a larger residuum after re-exploration (median survival, 24 months versus 10 months, p = 0.0001). Among the former, no difference in survival was seen between the patients who had residual disease < 2 cm at the beginning of the second-look and those who were surgically cytoreduced to < 2 cm. However, ovarian cancer recurred in all the patients with small or large macroscopic residuum after the second-look.
CONCLUSION: The complete resection of macroscopic persistent tumor seems to give ovarian cancer patients the highest likelihood of long-term survival and should represent the goal of surgical cytoreduction during second-look laparotomy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928134

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival.

Authors:  Kentaro Nakayama; Naomi Nakayama; Ben Davidson; Jim J-C Sheu; Natini Jinawath; Antonio Santillan; Ritu Salani; Robert E Bristow; Patrice J Morin; Robert J Kurman; Tian-Li Wang; Ie-Ming Shih
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-27       Impact factor: 11.205

2.  Loss of beclin 1 expression in ovarian cancer: A potential biomarker for predicting unfavorable outcomes.

Authors:  Toshiko Minamoto; Kentaro Nakayama; Kohei Nakamura; Hiroshi Katagiri; Razia Sultana; Tomoka Ishibashi; Masako Ishikawa; Hitomi Yamashita; Kaori Sanuki; Kouji Iida; Satoru Nakayama; Yoshiro Otsuki; Noriyuki Ishikawa; Satoru Kyo
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

3.  Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.

Authors:  Hiroshi Katagiri; Kentaro Nakayama; Sultana Razia; Kohei Nakamura; Emi Sato; Tomoka Ishibashi; Masako Ishikawa; Kouji Iida; Noriyoshi Ishikawa; Yoshiro Otsuki; Satoru Nakayama; Satoru Kyo
Journal:  Int J Oncol       Date:  2015-10-06       Impact factor: 5.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.